ClinicalTrials.gg
RecruitingNCT05398055Rocky-ZUpdated May 31, 2022

Efficacy of Azithromycin Plus Doxycycline Versus Doxycycline Plus Placebo in Patients With Rocky Mountain Spotted Fever

A Phase 3 interventional study of Azithromycin + Doxycycline and Placebo + Doxycycline in Rocky Mountain Spotted Fever, sponsored by Hospital General de Mexicali. Recruiting at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-31.

Sponsored by Hospital General de Mexicali · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to impove the pharmacological treatment of Rocky mountain spotted fever, since is a very ancient disease with an antibiotic therapy that have not changed much the mortality rates, being compared with the natural curse of the disease.

Read the detailed description

Rocky mountain spotted fever is a potentially fatal infectious disease wich is transmitted trough vectors. This particular infection is caused by Rickettsia rickettsii wich is a gramnegative intracellular bacilli. The pathophysiological mechanism and clinical manifestation is mainly due to the vascular affectation, since this pathogen has a tropism for endothelial cells. As it has been mentioned, this is an obligate intracellular pathogen, so the main choice with the antibiotic therapy is tetracyclines because of its action mechanism in the inhibition of the subunit 30S. The objective of the study is to prove new strategies of treatment to improve the pharmacological aproach by implementing Azithromycin, wich is a macrolide that inhibits de 50S subunit of the bacteria. Azithromycin has shown effectivity against other rickettsial diseases.

02

Conditions studied

  • Rocky Mountain Spotted Fever

Keywords

  • Rocky Mountain Spotted Fever
  • Azithromycin
  • Doxycycline
03

In context

Lead sponsor

Hospital General de Mexicali is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any gender
  • Over 18 years old
  • hospitalized in the internal medicine service, emergency department or intensive care unit of Hospital General de Mexicali (ISESALUD) or Hospital General Zona No. 30 (IMSS) with suspicion of RMSF that present fever and 2 or more of the next symptoms: headache, myalgia, rash, nausea, pharyngeal hyperemia, vomiting, abdominal pain, neurological disorders.
  • In addition to at least one of the next epidemiologycal fators: presence of vectors in areas of residence or endemic areas visited two weeks prior to the onset of symptoms, history of visiting or residing in areas with RMSF transmission in the last two weeks, existence of confirmed cases in the locality of origin, history of vector bite or contact with dogs in the two weeks.

Exclusion criteria

Exclusion Criteria:

  • Other clinical suspicion rather than RMSF
  • History of allergy to doxycycline, azithromycin, bean starch or bovine gelatin.
  • Not signing the
  • Pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    A

    Azithromycine group

    Drug: Azithromycin + Doxycycline

  • Placebo comparator
    B

    Placebo group

    Drug: Placebo + Doxycycline

Interventions

  • DrugAzithromycin + Doxycycline

    Drug pages: AzithromycinStudies of AzithromycinAzithromycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DoxycyclineStudies of DoxycyclineDoxycycline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days

    Also known as: A

  • DrugPlacebo + Doxycycline

    doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses

    Also known as: B

06

What researchers measure

Primary outcomes

  1. Mortality of azithromycin plus doxycycline vs doxycycline plus placebo

    Time frame: 3 years

Secondary outcomes

  1. Number of hospitalization days in each arm

    Time frame: 3 years

  2. Number of participants with renal replacement therapy.

    Time frame: 3 years

  3. Number of participants that required amines in both groups.

    Time frame: 3 years

  4. Number of fever days in both arms.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Dec 2025, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
May 31, 2022
StartActual
May 12, 2022
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
May 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05398055
Lead sponsor
Hospital General de Mexicali
Responsible party
Hiram Jaramillo Ramirez (Clinical professor, Hospital General de Mexicali) — Principal investigator
First posted
May 31, 2022
Start date
May 12, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
May 31, 2022

Study contacts

Hiram J. Jaramillo-Ramirez, MD
Contact
grupoinvestigacionmedica@gmail.com
686 135 8412
Gisel V. Licon-Martinez, MD
Contact
viviana.licon@uabc.edu.mx
686 194 5903
Hiram J Jaramillo-Ramirez, MD
principal investigator · Hospital General de Mexicali

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azithromycin · Doxycycline

Start the discussion